Titlebook: IgG4-Related Sclerosing Cholangitis; Terumi Kamisawa,Myung-Hwan Kim Book 2019 Springer Science+Business Media Singapore 2019 IgG4.Primary

真實(shí)的你

Treatment: Rituximab,ients, those with relapsing, recrudescent, or unresponsive disease are likely to respond to rituximab infusions. Patients who are intolerant of steroids are also likely to respond, and rituximab is effective as single-agent therapy. This chapter reviews the available evidence regarding rituximab the

Folklore

remission

Pathology,fficult because lesions of IgG4-SC are present in the deep part of the bile duct wall. Liver biopsies may obtain peripheral portal tracts packed with lymphoplasmacytic infiltration, but characteristic bile duct lesions are absent. Thus, the appropriate clinical setting is necessary to make a diagnos

Peak-Bone-Mass

在前面

gait-cycle

裂縫

Treatment: Immunomodulatory Drugs,t for IgG4-SC is corticosteroid therapy. Unfortunately, despite the high initial remission rates, 15–60% of patients will develop disease relapse either after cessation of steroid therapy or during the weaning of the steroid dose [6–9]. In Japan, to prevent relapses in type 1 AIP (including IgG4-SC)

蠟燭

pessimism

嘲弄

Itaru Naitoh,Takahiro Nakazawa,Hirotaka Ohara,Takashi Joh